JP2025506729A5 - - Google Patents
Info
- Publication number
- JP2025506729A5 JP2025506729A5 JP2024549135A JP2024549135A JP2025506729A5 JP 2025506729 A5 JP2025506729 A5 JP 2025506729A5 JP 2024549135 A JP2024549135 A JP 2024549135A JP 2024549135 A JP2024549135 A JP 2024549135A JP 2025506729 A5 JP2025506729 A5 JP 2025506729A5
- Authority
- JP
- Japan
- Prior art keywords
- isopropyl
- acetamide
- oxothieno
- pyrrolo
- triazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22315036 | 2022-02-21 | ||
| EP22315036.8 | 2022-02-21 | ||
| PCT/EP2023/054138 WO2023156643A1 (en) | 2022-02-21 | 2023-02-20 | Thienopyrrolotriazine compounds, their preparation and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506729A JP2025506729A (ja) | 2025-03-13 |
| JP2025506729A5 true JP2025506729A5 (cg-RX-API-DMAC7.html) | 2026-02-27 |
Family
ID=81326677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024549135A Pending JP2025506729A (ja) | 2022-02-21 | 2023-02-20 | チエノピロロトリアジン化合物、それらの調製及びそれらの治療的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250129091A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4482841B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506729A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240151767A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118843632A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023222186A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3244475A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024010803A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314781A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010216A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023156643A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116375728B (zh) * | 2021-12-31 | 2025-06-10 | 成都赜灵生物医药科技有限公司 | 噻吩吡咯并三嗪酮类化合物及其用途 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168012B2 (en) * | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| US20230203064A1 (en) * | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
-
2023
- 2023-02-20 WO PCT/EP2023/054138 patent/WO2023156643A1/en not_active Ceased
- 2023-02-20 MX MX2024010216A patent/MX2024010216A/es unknown
- 2023-02-20 EP EP23705039.8A patent/EP4482841B1/en active Active
- 2023-02-20 AU AU2023222186A patent/AU2023222186A1/en active Pending
- 2023-02-20 JP JP2024549135A patent/JP2025506729A/ja active Pending
- 2023-02-20 IL IL314781A patent/IL314781A/en unknown
- 2023-02-20 CN CN202380021421.XA patent/CN118843632A/zh active Pending
- 2023-02-20 US US18/834,987 patent/US20250129091A1/en active Pending
- 2023-02-20 KR KR1020247027615A patent/KR20240151767A/ko active Pending
- 2023-02-20 CA CA3244475A patent/CA3244475A1/en active Pending
-
2024
- 2024-08-08 CO CONC2024/0010803A patent/CO2024010803A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4648703B2 (ja) | 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物 | |
| JP2019505541A5 (cg-RX-API-DMAC7.html) | ||
| EP1856045B1 (en) | 1-acetic acid-indole derivatives with pgd2 antagonist activity | |
| CN1444584A (zh) | 依赖细胞周期蛋白的激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]甲酰胺抑制剂 | |
| JP2012523440A5 (cg-RX-API-DMAC7.html) | ||
| JP2019500352A5 (cg-RX-API-DMAC7.html) | ||
| CN1285820A (zh) | 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂 | |
| JP2010516635A5 (cg-RX-API-DMAC7.html) | ||
| JP2012515209A5 (cg-RX-API-DMAC7.html) | ||
| JP2010518026A5 (cg-RX-API-DMAC7.html) | ||
| JP2014531464A (ja) | 選択的NK−3受容体拮抗薬としての新規なキラルN−アシル−5,6,7,(8位置換)−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、その医薬組成物、NK−3受容体媒介性障害で使用する方法およびキラル合成 | |
| JP2021528446A5 (cg-RX-API-DMAC7.html) | ||
| JP2007524710A5 (cg-RX-API-DMAC7.html) | ||
| JP2013010790A5 (cg-RX-API-DMAC7.html) | ||
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| JP2021532124A (ja) | Nlrp3インフラマソーム阻害剤 | |
| PE20220970A1 (es) | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones | |
| US11136309B2 (en) | Metalloenzyme inhibitor compounds | |
| JP2012507525A5 (cg-RX-API-DMAC7.html) | ||
| JP2024540318A5 (cg-RX-API-DMAC7.html) | ||
| MX2012003720A (es) | N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos. | |
| JP2023507569A5 (cg-RX-API-DMAC7.html) | ||
| US6613911B2 (en) | Process for preparing arylacetylaminothiazoles | |
| JP2023552838A5 (cg-RX-API-DMAC7.html) | ||
| JP2021529168A5 (cg-RX-API-DMAC7.html) |